817 related articles for article (PubMed ID: 18276926)
1. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
Duan SZ; Usher MG; Mortensen RM
Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
[TBL] [Abstract][Full Text] [Related]
2. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
Fogo AB
Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
4. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
Panunti B; Fonseca V
Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
[TBL] [Abstract][Full Text] [Related]
5. [Effects of PPARgamma agonist on dyslipidemia and atherosclerosis].
Komatsu A; Node K
Nihon Rinsho; 2010 Feb; 68(2):294-8. PubMed ID: 20158099
[TBL] [Abstract][Full Text] [Related]
6. Modulation of cardiac and aortic peroxisome proliferator-activated receptor-gamma expression by oxidative stress in chronically glucose-fed rats.
El Midaoui A; Wu L; Wang R; de Champlain J
Am J Hypertens; 2006 Apr; 19(4):407-12. PubMed ID: 16580578
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice.
Thorp E; Kuriakose G; Shah YM; Gonzalez FJ; Tabas I
Circulation; 2007 Nov; 116(19):2182-90. PubMed ID: 17967777
[TBL] [Abstract][Full Text] [Related]
8. Effects of PPAR-gamma knock-down and hyperglycemia on insulin signaling in vascular smooth muscle cells from hypertensive rats.
Pandey NR; Benkirane K; Amiri F; Schiffrin EL
J Cardiovasc Pharmacol; 2007 Jun; 49(6):346-54. PubMed ID: 17577098
[TBL] [Abstract][Full Text] [Related]
9. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
Libby P; Plutzky J
Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
[TBL] [Abstract][Full Text] [Related]
10. Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma.
Zieleniak A; Wójcik M; Woźniak LA
Arch Immunol Ther Exp (Warsz); 2008; 56(5):331-45. PubMed ID: 18836859
[TBL] [Abstract][Full Text] [Related]
11. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of prostaglandin A(1) in rat models of permanent focal cerebral ischemia are associated with nuclear factor-kappaB inhibition and peroxisome proliferator-activated receptor-gamma up-regulation.
Zhang HL; Gu ZL; Savitz SI; Han F; Fukunaga K; Qin ZH
J Neurosci Res; 2008 Apr; 86(5):1132-41. PubMed ID: 18074385
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone and dexamethasone induce adipogenesis in D1 bone marrow stromal cell line, but not through the peroxisome proliferator-activated receptor-gamma pathway.
Hung SH; Yeh CH; Huang HT; Wu P; Ho ML; Chen CH; Wang C; Chao D; Wang GJ
Life Sci; 2008 Mar; 82(11-12):561-9. PubMed ID: 18272184
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor gamma agonist rosiglitazone attenuates oxyhemoglobin-induced Toll-like receptor 4 expression in vascular smooth muscle cells.
Wu Y; Zhao XD; Zhuang Z; Xue YJ; Cheng HL; Yin HX; Shi JX
Brain Res; 2010 Mar; 1322():102-8. PubMed ID: 20132800
[TBL] [Abstract][Full Text] [Related]
15. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
Blaschke F; Caglayan E; Hsueh WA
Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
[TBL] [Abstract][Full Text] [Related]
17. PPAR gamma as a metabolic regulator: insights from genomics and pharmacology.
Savage DB
Expert Rev Mol Med; 2005 Jan; 7(1):1-16. PubMed ID: 15673477
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats.
Weissgarten J; Berman S; Efrati S; Rapoport M; Averbukh Z; Feldman L
Nephrol Dial Transplant; 2006 May; 21(5):1198-204. PubMed ID: 16449288
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
